One Test. Every Biomarker. Every Solid Tumor PanCan CGP Assay

by Posted on

Cancer is no longer defined solely by its tissue of origin—it is driven by a complex network of genomic alterations that determine disease progression, therapeutic response, and clinical outcomes. As precision oncology continues to evolve, sequential single-gene testing is rapidly becoming insufficient for modern cancer care. Clinicians today require a comprehensive molecular portrait that captures actionable variants, predictive biomarkers, and resistance mechanisms in a single workflow. The Genes2Me PanCan Cancer Genomic Profiling (CGP) Assay has been developed to meet this need, offering a hybrid capture-based Next-Generation Sequencing (NGS) solution that interrogates 774 clinically relevant genes, multiple biomarker classes, and clinically actionable genomic signatures in one assay. Designed according to internationally accepted ACMG, AMP, NCCN, and ASCO guidelines, the assay enables comprehensive genomic profiling across a wide spectrum of solid tumors while minimizing tissue consumption and reducing turnaround time.

One Assay Covering the Entire Molecular Landscape of Solid Tumors

Unlike conventional disease-specific panels, the PanCan CGP Assay follows a tumor-agnostic approach, enabling comprehensive profiling of multiple solid malignancies—including lung, breast, colorectal, ovarian, pancreatic, prostate, gastric, thyroid, liver, bladder, cervical cancers, gliomas, melanoma, and several rare tumors—using a single standardized workflow. The assay simultaneously detects Single Nucleotide Variants (SNVs), Insertions and Deletions (InDels), Copy Number Variations (CNVs), Microsatellite Instability (MSI), Tumor Mutational Burden (TMB), Homologous Recombination Deficiency (HRD) Score, along with clinically significant biomarkers such as MET Exon 14 Skipping, EGFR Exon 2–7 Skipping, ERBB2 (HER2) amplification, PD-L1 DNA amplification, 1p/1Gq co-deletion, and TERT promoter alterations. By consolidating this extensive biomarker repertoire into a single assay, laboratories can eliminate multiple sequential tests, conserve precious biopsy tissue, and deliver faster, clinically actionable insights for precision treatment selection.

Comprehensive DNA and RNA Fusion Detection with Tissue and Liquid Biopsy Support

Gene fusions represent some of the most actionable biomarkers in oncology, yet their accurate detection often requires complementary analytical approaches. The Genes2Me PanCan CGP Assay integrates both DNA- and RNA-based fusion analysis, combining structural variant detection at the genomic level with confirmation of expressed fusion transcripts. This dual-modality strategy significantly improves the detection of clinically relevant rearrangements while reducing the likelihood of missed fusion events. The assay supports analysis of 105 RNA fusion targets alongside DNA alterations, providing a truly comprehensive molecular assessment within a single workflow. Furthermore, the assay is optimized for both FFPE/fresh tissue and circulating tumor DNA (ctDNA) applications. Standard tissue samples require approximately 4 GB of sequencing data to achieve robust variant detection, whereas the PanCan Liquid Biopsy workflow utilizes approximately 40 GB of sequencing data with ultra-deep coverage to enable highly sensitive detection of low-frequency ctDNA variants present in plasma. This ten-fold increase in sequencing depth ensures exceptional analytical sensitivity for liquid biopsy, making the platform equally powerful for tissue-based diagnostics and minimally invasive disease monitoring.

A Complete End-to-End Precision Oncology Solution

Comprehensive genomic profiling extends far beyond sequencing—it requires an integrated ecosystem capable of transforming raw sequencing data into clinically meaningful insights. The Genes2Me PanCan CGP workflow combines hybrid capture-based enrichment, EZY Autoprep-enabled automated liquid handling for standardized library preparation, precise reagent dispensing, controlled sample processing, and reduced hands-on variability, along with assay compatibility across major sequencing platforms including Illumina, MGI, Thermo Fisher Scientific, and Element Biosciences, and automated interpretation through the CliSeq Interpreter bioinformatics platform. Backed by robust analytical performance, including >GG% coverage uniformity, G7% reproducibility, 78–G0% on-target ratio, and G8.G% sensitivity at 1% Variant Allele Frequency (VAF), the assay delivers reliable, reproducible, and clinically actionable genomic information. By integrating broad genomic coverage, DNA and RNA fusion detection, comprehensive biomarker analysis, automation-supported consistency in pre-sequencing library preparation, and validated tissue and liquid biopsy workflows into a single solution, the Genes2Me PanCan CGP Assay empowers laboratories and clinicians to unlock the full potential of precision oncology—because the future of cancer diagnostics lies not in asking one question at a time, but in obtaining every answer from a single test.

Published by Genes2Me

Established in 2016, Genes2Me is a leading molecular diagnostics company committed to transforming healthcare through innovative, high-quality in vitro diagnostic (IVD) solutions. Built on a strong foundation of scientific excellence and precision engineering, Genes2Me develops and manufactures advanced diagnostic technologies that enable accurate, reliable, and timely clinical decision-making across diverse healthcare settings worldwide. With a comprehensive and rapidly expanding portfolio, Genes2Me offers cutting-edge solutions across molecular diagnostics, including Next Generation Sequencing (NGS) clinical assays, point-of-care (POC) testing platforms, RT-PCR kits and instruments, as well as nucleic acid extraction kits and automation systems. Designed to meet the evolving needs of modern laboratories and clinicians, our products combine performance, scalability, and operational efficiency. A vast majority of Genes2Me products are CE-IVD marked, reflecting our commitment to global quality benchmarks, regulatory compliance, and uncompromising product standards. At the heart of our innovation are proprietary platforms such as OnePCR and Rapi-Q, developed to deliver rapid, multiplex, and highly sensitive molecular detection with streamlined workflows and minimal turnaround time. OnePCR integrates automated nucleic acid extraction and RT-PCR into a single, seamless workflow, enabling the detection of up to 20 targets from a single sample with exceptional precision and efficiency. The Rapi-Q series is engineered for fast, sensitive, and multiplex testing with a larger throughput, empowering healthcare providers with timely diagnostic insights that support improved patient outcomes. In genomics, Genes2Me offers one of the industry’s most comprehensive NGS clinical assay portfolios, spanning oncology, liquid biopsy, whole exome sequencing, NIPT and pharmacogenomics. Complementing this portfolio is EZY AutoPrep, our advanced automated library preparation workstation designed to optimize NGS library preparation through enhanced accuracy, reproducibility, and scalability. Our genomics ecosystem is further strengthened by CliSeq Interpreter, a cloud-based bioinformatics platform that enables accurate, flexible, and intuitive interpretation of complex genomic data, helping laboratories generate high-confidence insights with efficiency and ease. Driven by innovation, quality, and a global vision, Genes2Me continues to redefine the future of molecular diagnostics—delivering integrated solutions that advance precision medicine and improve lives worldwide.